National Cancer Institute to Grant Exclusive Patent License to Xsto BioSciences for Anti-GPC3 Cancer Treatment

Summary

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting Xsto BioSciences, Inc., a California-based company, an exclusive patent license to develop an anti-GPC3 radionuclide immunoconjugate for treating cancers that express the GPC3 protein.